openPR Logo
Press release

Treating Infant Respiratory Distress Disorders with Pulmonary Surfactants

08-09-2011 09:50 AM CET | Health & Medicine

Press release from: Infasurf

Treating Infant Respiratory Distress Disorders with Pulmonary

FOR IMMEDIATE RELEASE
New York, U.S.:Infants who experience respiratory distress disorders are commonly treated with pulmonary surfactants. Respiratory distress syndrome (RDS) is a condition in which the lungs are not fully developed and the infant has trouble breathing on his or her own. This is due to insufficient amounts of surfactant, which is a naturally occurring substance that coats the lungs and allows them to function properly. Infants who are born prematurely – approximately six weeks before their due date – sometimes do not have enough natural surfactant to breathe properly.

Without sufficient amounts of pulmonary surfactant, an infant's lungs might collapse. This means infants with respiratory distress disorders may not get enough oxygen to support organ function. Respiratory distress disorder is apparent at birth, or directly following birth. Symptoms can include flaring the nostrils, grunting, or rapid, shallow breathing.

Respiratory Distress Disorder Treatment Options
An infant who experiences respiratory distress disorders due to insufficient pulmonary surfactant should be treated as soon as RDS is diagnosed. This typically will happen directly after birth. Infants with RDS need specialized care in a neonatal intensive care unit (NICU). Babies in the NICU receive care from doctors and nurses who specialize in treating infant respiratory distress disorders, among others.

Once in the NICU, infants need immediate help with their breathing. This can be achieved through a variety of different treatments and therapies. For example, an infant with respiratory distress might receive pulmonary surfactant replacement therapy, which involves administering medication. Curosurf, Infasurf, and Survanta are common artificial pulmonary surfactants that treat infant respiratory distress disorders. These surfactants are administered until the infant is able to produce surfactant on his or her own, and the lungs become more developed. Artificial pulmonary surfactants are typically administered through a tube that sends the medication directly into the infant’s lungs.

Pulmonary surfactant therapy should only be administered by medical professionals within the confines of an NICU. Infants with RDS will usually receive pulmonary surfactant therapy several times a day for a few days, or until lung function improves.

Another treatment option for infants with respiratory distress disorders it to receive breathing support from a mechanical ventilator or a nasal continuous positive airway pressure machine (NCPAP). This machine gently moves air into the lungs through prongs placed in the baby’s nostrils.

For further enquires related to ONY, Inc. and Infasurf, please free to email at info@onyinc.com or visit www.infasurf.com now.

ONY, Inc. of Amherst, New York is the owner of Infasurf (calfactant). Infasurf is derived from natural surfactants to offer relief from this syndrome.

ONY, Inc.
1576 Sweet Home Rd.
Amherst, NY 14228
Tel: (716) 636-9096
Toll-free: (877) 274-4469
info@onyinc.com
http://www.infasurf.com/
Monday to Friday, 9 a.m. to 5 p.m. Eastern, excluding holidays

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Treating Infant Respiratory Distress Disorders with Pulmonary Surfactants here

News-ID: 186877 • Views: 1684

More Releases from Infasurf

Respiratory Distress Syndrome ("Blue Baby Syndrome") in Infants
FOR IMMEDIATE RELEASE New York, U.S.: Infants who are born prematurely are sometimes diagnosed with respiratory distress syndrome (RDS), also known as "blue baby syndrome". The condition is caused by a lack of surfactant, which is a naturally occurring substance that helps the lungs function properly. Surfactant is usually produced just a few weeks before birth. When premature infants -- born around six weeks before their due date -- don' t

More Releases for Respiratory

Global Respiratory Monitoring Devices Market | Global Respiratory Monitoring Dev …
Respiration is a unique process of human lives, which jumps at the time of birth and lasts till decease. A healthy human body is skilled of respiration process for numerous years but, due to rising levels of pollution in urban cities and lives concerning tobacco smoking, clogging of airways and other structures of the lung is turning into a common concern across the globe. The respiratory monitoring devices market comprises
Global Respiratory Protection Equipment Market Research Report
This report studies the global Respiratory Protection Equipment market status and forecast, categorizes the global Respiratory Protection Equipment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report 3M Avon Protection Systems Bullard Group Honeywell International MSA Safety Alpha Pro Tech Ansell
Respiratory Care Devices Market By Product
The respiratory care devices market report provides historical data along with future forecast and detailed analysis for respiratory care devices market on a global, regional and country level. The study provides us with historical data for the year 2012 to 2016 along with forecast from 2017 to 2022 based on volume (Mn Units) as well as revenue (USD Million). This research study helps the purchaser to understand the various drivers
Respiratory Monitoring Devices Industry Trends
Global Respiratory Monitoring Devices Market: Snapshot Factors at the forefront of driving the demand in the global respiratory monitoring devices market are the rising number of cigarette smokers and a worsening air quality on account of rampant pollution. Further, a burgeoning geriatric population highly susceptible to lung diseases has also pushed up the demand in the market. Countering its growth, however, are the steep prices of newer, sophisticated respiratory monitoring devices,
Respiratory Monitoring Devices Market 2015
While a handful players have taken up a majority share in the global distribution of respiratory monitoring devices, the remainder of the market is marked by a very large number of small players. Of the key multinationals dominating the distribution of respiratory monitoring devices in 2014, CareFusion Corporation, Smiths Medical, and ResMed, Inc., had garnered a total share of 54.2% in terms of value. As described in a research report released
Respiratory Monitoring Devices Market Research Report 2023
While a handful players have taken up a majority share in the global distribution of respiratory monitoring devices, the remainder of the market is marked by a very large number of small players. Of the key multinationals dominating the distribution of respiratory monitoring devices in 2014, CareFusion Corporation, Smiths Medical, and ResMed, Inc., had garnered a total share of 54.2% in terms of value. As described in a research report released